Pacira Pharmaceuticals (PCRX) Receives News Sentiment Rating of 0.18
News coverage about Pacira Pharmaceuticals (NASDAQ:PCRX) has been trending somewhat positive this week, Accern Sentiment reports. Accern ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Pacira Pharmaceuticals earned a news impact score of 0.18 on Accern’s scale. Accern also assigned news articles about the company an impact score of 47.0151661053707 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the media stories that may have impacted Accern Sentiment’s rankings:
- Pacira Pharmaceuticals, Inc. (PCRX) Price Target Raised to $38.00 (americanbankingnews.com)
- Pacira Pharmaceuticals’ (PCRX) “Hold” Rating Reiterated at Oppenheimer Holdings, Inc. (americanbankingnews.com)
- Pacira Pharmaceuticals (PCRX) PT Raised to $39 at BMO Capital on 3Q Report; ‘Higher Gross Margin and Lower R&D’ – StreetInsider.com (streetinsider.com)
- Pacira (PCRX) Posts Earnings in Q3, Revenues Lag Estimates – Nasdaq (nasdaq.com)
- Pacira Pharmaceuticals (PCRX) Q3 2017 Results – Earnings Call Transcript – Seeking Alpha (seekingalpha.com)
Shares of Pacira Pharmaceuticals (NASDAQ PCRX) traded up $1.90 during trading hours on Friday, hitting $42.05. 778,727 shares of the company’s stock were exchanged, compared to its average volume of 840,018. Pacira Pharmaceuticals has a 1 year low of $29.81 and a 1 year high of $58.95. The company has a current ratio of 7.84, a quick ratio of 7.26 and a debt-to-equity ratio of 1.03.
Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its quarterly earnings results on Wednesday, November 8th. The company reported $0.11 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.04) by $0.15. Pacira Pharmaceuticals had a negative net margin of 18.25% and a negative return on equity of 13.97%. The company had revenue of $67.30 million during the quarter, compared to the consensus estimate of $68.99 million. During the same quarter in the prior year, the firm posted $0.20 EPS. The firm’s quarterly revenue was down 1.6% on a year-over-year basis. equities analysts expect that Pacira Pharmaceuticals will post -0.96 earnings per share for the current fiscal year.
Several equities research analysts have commented on the stock. Canaccord Genuity boosted their price target on shares of Pacira Pharmaceuticals from $33.00 to $38.00 and gave the stock a “hold” rating in a research report on Thursday. Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of Pacira Pharmaceuticals in a research report on Thursday. HC Wainwright reissued a “buy” rating and set a $52.00 price target on shares of Pacira Pharmaceuticals in a research report on Thursday. Jefferies Group LLC cut their price target on shares of Pacira Pharmaceuticals to $52.00 and set a “buy” rating on the stock in a research report on Thursday. Finally, BMO Capital Markets boosted their price target on shares of Pacira Pharmaceuticals from $38.00 to $39.00 and gave the stock a “market perform” rating in a research report on Wednesday. Three equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $49.71.
COPYRIGHT VIOLATION WARNING: This article was first published by Watch List News and is owned by of Watch List News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this article can be viewed at https://www.watchlistnews.com/pacira-pharmaceuticals-pcrx-receives-news-sentiment-rating-of-0-18/1694194.html.
In related news, CEO David M. Stack sold 28,885 shares of the stock in a transaction that occurred on Tuesday, August 15th. The shares were sold at an average price of $36.37, for a total value of $1,050,547.45. Following the completion of the transaction, the chief executive officer now owns 159,164 shares of the company’s stock, valued at approximately $5,788,794.68. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CAO Kristen Marie Williams sold 3,461 shares of the stock in a transaction that occurred on Tuesday, August 15th. The shares were sold at an average price of $36.75, for a total transaction of $127,191.75. Following the completion of the transaction, the chief accounting officer now directly owns 21,312 shares of the company’s stock, valued at approximately $783,216. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 33,390 shares of company stock valued at $1,215,480. 6.60% of the stock is currently owned by insiders.
About Pacira Pharmaceuticals
Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.
Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.